Vaxart, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Vaxart, Inc. (VXRT) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$1.60 million for the 12-month period ending 2017-06-30, per its 10-K filed 2017-09-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-09-01
- Vaxart, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $4.90M.
- Vaxart, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$14.70M.
- Vaxart, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $1.30M, a 53.57% decline year-over-year.
- Vaxart, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $6.90M.
- Vaxart, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$1.60M, a 223.08% decline from fiscal 2016.
- Vaxart, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $1.30M.
- Vaxart, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$19.40M.
- Vaxart, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$10.10M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-06-30 | $4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-01 | -$9.80M derived: sum of 2 quarters · filed 2017-09-01 | -$8.50M derived: sum of 3 quarters · filed 2017-09-01 | -$1.60M 10-K · filed 2017-09-01 |
| 2017-03-31 | -$14.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-08 | -$13.40M derived: sum of 2 quarters · filed 2017-05-08 | -$6.50M 10-Q · filed 2017-05-08 | -$6.50M derived: sum of 4 quarters · filed 2017-09-01 |
| 2016-12-31 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-06 | $8.20M 10-Q · filed 2017-02-06 | $8.20M derived: sum of 3 quarters · filed 2017-09-01 | $6.90M derived: sum of 4 quarters · filed 2017-09-01 |
| 2016-09-30 | $6.90M 10-Q · filed 2016-11-08 | $6.90M derived: sum of 2 quarters · filed 2017-09-01 | $5.60M derived: sum of 3 quarters · filed 2017-09-01 | $8.40M derived: sum of 4 quarters · filed 2017-09-01 |
| 2016-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-01 | -$1.30M derived: sum of 2 quarters · filed 2017-09-01 | $1.50M derived: sum of 3 quarters · filed 2017-09-01 | $1.30M 10-K · filed 2017-09-01 |
| 2016-03-31 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-08 | $1.50M derived: sum of 2 quarters · filed 2017-05-08 | $1.30M 10-Q · filed 2017-05-08 | |
| 2015-12-31 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-06 | $2.60M 10-Q · filed 2017-02-06 | ||
| 2015-09-30 | -$200.00K 10-Q · filed 2016-11-08 | |||
| 2015-06-30 | -$19.40M 10-K · filed 2016-09-13 | |||
| 2014-06-30 | -$10.10M 10-K · filed 2016-09-13 | |||
| 2012-09-30 | $2.08M 10-Q · filed 2012-11-08 | |||
| 2011-09-24 | $48.20M 10-Q · filed 2012-11-08 | |||
| 2010-09-25 | -$15.30M 10-Q · filed 2011-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |